TickerFacts.

Compare

Elite Pharmaceuticals Inc vs Macrogenics Inc vs Karyopharm Therapeutics Inc. vs Heron Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearElite Pharmaceuticals Inc
ELTP		Macrogenics Inc
MGNX		Karyopharm Therapeutics Inc.
KPTI		Heron Therapeutics, Inc.
HRTX
Year ended2026-03-312025-12-312025-12-312025-12-31
Revenue$148.87M$149.50M$146.07M$154.90M
Revenue growth (YoY)+77.1%-0.3%+0.6%+7.4%
Gross margin50.4%n/an/a73.3%
Operating margin33.0%-48.7%-62.1%-1.6%
Net margin30.1%-49.9%-134.2%-13.0%
Net income$44.87M-$74.62M-$196.04M-$20.20M
EPS (Diluted)$0.03-$1.18-$17.93-$0.12
Operating cash flow$23.75M-$81.04M-$75.37M-$27.59M
Free cash flow$22.82M-$82.95M-$75.37M-$27.91M
Cash & equivalentsn/a$57.22M$60.54M$28.65M
Total assets$138.29M$256.85M$108.42M$255.88M
Total liabilities$39.41M$201.25M$401.34M$241.54M
Shareholders' equity$98.88M$55.59M-$292.93M$14.33M
Return on year-end equity45.4%-134.2%n/a-140.9%
Shares outstanding1.08B63.32M18.31M188.31M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearElite Pharmaceuticals IncMacrogenics IncKaryopharm Therapeutics Inc.Heron Therapeutics, Inc.
Latest$148.87M
Ended 2026-03-31		$149.50M
Ended 2025-12-31		$146.07M
Ended 2025-12-31		$154.90M
Ended 2025-12-31
1 year earlier$84.04M
Ended 2025-03-31		$149.96M
Ended 2024-12-31		$145.24M
Ended 2024-12-31		$144.28M
Ended 2024-12-31
2 years earlier$56.63M
Ended 2024-03-31		$58.75M
Ended 2023-12-31		$146.03M
Ended 2023-12-31		$127.04M
Ended 2023-12-31
3 years earlier$34.16M
Ended 2023-03-31		$151.94M
Ended 2022-12-31		$157.07M
Ended 2022-12-31		$107.67M
Ended 2022-12-31
4 years earlier$32.26M
Ended 2022-03-31		$77.45M
Ended 2021-12-31		$209.82M
Ended 2021-12-31		$86.35M
Ended 2021-12-31